A. Khan

Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients

R. Schachar, Q. Nguyen, C. Nduaka, 2012, Eye.

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

A. Tinker, K. Gelmon, L. Seymour, 2020, Investigational New Drugs.